ALT|Altimmune Inc|Price:2.915|Chg%:-0.10

More Details of Altimmune Inc Company

Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.

Altimmune Inc Info



Ticker SymbolALT

Company nameAltimmune Inc

IPO dateOct 06, 2005

CEODurso (Jerome Benedict)

Number of employees59

Security typeOrdinary Share

Fiscal year-endOct 06

Address910 Clopper Road

CityGAITHERSBURG

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code20878-1361

Phone12406541450

Websitehttps://altimmune.com/

Ticker SymbolALT

IPO dateOct 06, 2005

CEODurso (Jerome Benedict)

Company Executives of Altimmune Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Vipin K. Garg, Ph.D.

Director

424.52K

+16.36%

Mr. Raymond M. (Ray) Jordt

Chief Business Officer

70.11K

+48.26%

Mr. Jerome Benedict (Jerry) Durso

Chairman of the Board, President, Chief Executive Officer

47.50K

+31.58%

Mr. Gregory L. (Greg) Weaver

Chief Financial Officer

38.08K

+26.26%

Dr. Mitchel B. (Mitch) Sayare, Ph.D.

Independent Director

26.36K

--

Mr. John M. Gill

Independent Director

21.70K

+42.40%

Brig. Gen. (Retd.) Klaus O. Schafer, M.D.

Independent Director

9.18K

--

Dr. Catherine Angell Sohn, Pharm.D.

Independent Director

1.50K

--

Dr. Diane K. Jorkasky, M.D.

Independent Director

527.00

--

Dr. M. Scot Roberts, Ph.D.

Chief Scientific Officer

--

Name

Name/Position

Position

Shareholding

Change

Dr. Vipin K. Garg, Ph.D.

Director

424.52K

+16.36%

Mr. Raymond M. (Ray) Jordt

Chief Business Officer

70.11K

+48.26%

Mr. Jerome Benedict (Jerry) Durso

Chairman of the Board, President, Chief Executive Officer

47.50K

+31.58%

Mr. Gregory L. (Greg) Weaver

Chief Financial Officer

38.08K

+26.26%

Dr. Mitchel B. (Mitch) Sayare, Ph.D.

Independent Director

26.36K

--

Mr. John M. Gill

Independent Director

21.70K

+42.40%

Revenue Breakdown

Relevant data have not been disclosed by the company yet.

Relevant data have not been disclosed by the company yet.

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: 21 hours ago

Shareholders

Shareholder Types

Shareholders

Proportion

Deep Track Capital LP

9.91%

BlackRock Institutional Trust Company, N.A.

4.04%

State Street Investment Management (US)

3.68%

Viking Global Investors LP

3.45%

RA Capital Management, LP

3.35%

Other

75.57%

Shareholders

Proportion

Deep Track Capital LP

9.91%

BlackRock Institutional Trust Company, N.A.

4.04%

State Street Investment Management (US)

3.68%

Viking Global Investors LP

3.45%

RA Capital Management, LP

3.35%

Other

75.57%

Shareholder Types

Shareholders

Proportion

Investment Advisor

18.22%

Hedge Fund

14.76%

Investment Advisor/Hedge Fund

11.03%

Venture Capital

3.35%

Research Firm

2.65%

Individual Investor

0.41%

Bank and Trust

0.23%

Pension Fund

0.03%

Insurance Company

0.02%

Other

49.30%

Institutional Shareholding



Updated: Wed, Apr 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q1

416

57.72M

30.53%

+4.64M

2025Q4

397

42.20M

45.25%

+62.13K

2025Q3

414

42.28M

51.76%

+3.92M

2025Q2

414

38.35M

59.50%

-499.87K

2025Q1

418

38.87M

69.79%

-15.45M

2024Q4

424

41.24M

78.28%

+1.10M

2024Q3

424

40.14M

86.96%

-2.89M

2024Q2

422

42.99M

89.21%

-1.89M

2024Q1

404

45.12M

79.71%

-11.40M

2023Q4

374

33.97M

69.19%

+3.12M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

BlackRock Institutional Trust Company, N.A.

7.85M

6.04%

+2.05M

+35.43%

Dec 31, 2025

State Street Investment Management (US)

5.12M

3.94%

+1.52M

+42.16%

Dec 31, 2025

Nuveen LLC

1.24M

0.95%

+1.04M

+516.93%

Dec 31, 2025

Geode Capital Management, L.L.C.

2.29M

1.76%

+275.02K

+13.63%

Dec 31, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

Invesco NASDAQ Future Gen 200 ETF

0.57%

Virtus LifeSci Biotech Clinical Trials ETF

0.38%

State Street SPDR S&P Biotech ETF

0.15%

Fidelity Enhanced Small Cap ETF

0.09%

Direxion Daily S&P Biotech Bull 3X Shares

0.09%

iShares Micro-Cap ETF

0.06%

ProShares Ultra Nasdaq Biotechnology

0.04%

iShares Biotechnology ETF

0.03%

Invesco Nasdaq Biotechnology ETF

0.03%

iShares Russell 2000 Growth ETF

0.02%

Invesco NASDAQ Future Gen 200 ETF

Proportion0.57%

Virtus LifeSci Biotech Clinical Trials ETF

Proportion0.38%

State Street SPDR S&P Biotech ETF

Proportion0.15%

Fidelity Enhanced Small Cap ETF

Proportion0.09%

Direxion Daily S&P Biotech Bull 3X Shares

Proportion0.09%

iShares Micro-Cap ETF

Proportion0.06%

ProShares Ultra Nasdaq Biotechnology

Proportion0.04%

iShares Biotechnology ETF

Proportion0.03%

Invesco Nasdaq Biotechnology ETF

Proportion0.03%

iShares Russell 2000 Growth ETF

Proportion0.02%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data